Managing bronchiolitis obliterans syndrome (BOS) and chronic lung allograft dysfunction (CLAD) in children: What does the future hold?

Pediatric Drugs

Volumn 15, Issue 4, 2013, Pages 281-289

  Snell, Gregory I ^a   Paraskeva, Miranda ^a   Westall, Glen P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; BORTEZOMIB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17 ANTAGONIST; LYMPHOCYTE ANTIBODY; MACROLIDE; MONTELUKAST; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIRFENIDONE; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIBODY MEDIATED REJECTION; BRONCHIOLITIS OBLITERANS; CHRONIC LUNG ALLOGRAFT DYSFUNCTION; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SUBSTITUTION; GRAFT DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LONG TERM CARE; LUNG INJURY; LUNG TRANSPLANTATION; LYMPH NODE IRRADIATION; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESTRICTIVE ALLOGRAFT SYNDROME; RETRANSPLANTATION; REVIEW; SPIROMETRY; STEM CELL TRANSPLANTATION;

BRONCHIOLITIS OBLITERANS; CHILD; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG TRANSPLANTATION; PRIMARY GRAFT DYSFUNCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84880770864     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0026-4     Document Type: Review

References (73)

1. Benden C, Edwards LB, Kucheryavaya AY, Christie JD, Dipchand AI, Dobbels F, et al. The Registry of the International Society for Heart and Lung Transplantation: fifteenth pediatric lung and heart-lung transplantation report - 2012. J Heart Lung Transplant. 2012;31(10):1087-95.
2. Solomon M, Grasemann H, Keshavjee S. Pediatric lung transplantation. Pediatr Clin North Am. 2010;57(2):375-91.
3. Sweet SC. Pediatric lung transplantation. Proceed Am Thorac Soc. 2009;6(1):122-7.
4. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21(3):297-310. (Pubitemid 34224094)
5. Verleden SE, Verleden GM, Vanaudenaerde BM. Phenotyping BOS could improve understanding of mechanisms involved. J Heart Lung Transplant. 2010;30(1):112.
6. Woodrow JP, Shlobin OA, Barnett SD, Burton N, Nathan SD. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2010;29(10):1159-64.
7. Snell G, Levvey B, Westall G. Non-bronchiolitis obliterans syndrome (BOS) forms of chronic lung allograft dysfunction (CLAD). In: Hirsch J, Elssner A, Masur G, Maier KL, editors. Bronchiolitis obliterans syndrome after lung transplantation. New York: Springer; 2013.
8. Valapour M, Paulson K, Smith JM, Hertz MI, Skeans MA, Heubner BM, et al. OPTN/SRTR 2011 annual data report: lung. Am J Transplant. 2013;13(Suppl 1):149-77.
9. Rosen JB, Smith EO, Schecter MG, Mallory GB, Elidemir O. Decline in 25% to 75% forced expiratory flow as an early predictor of chronic airway rejection in pediatric lung transplant recipients. J Heart Lung Transplant. 2012;31(12):1288-92.
10. Snell GI, Westall GP. The contribution of airway ischemia and vascular remodelling to the pathophysiology of bronchiolitis obliterans syndrome and chronic lung allograft dysfunction. Curr Opin Organ Transplant. 2010;15(5):558-62.
11. Williams TJ, Snell GI. Early and long-term functional outcomes in unilateral, bilateral, and living-related transplant recipients. Clin Chest Med. 1997;18(2):245-57. (Pubitemid 27247134)
12. Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2010;30(7):735-42.
13. Sato M, Hwang DM, Waddell TK, Singer LG, Keshavjee S. Progression pattern of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant. 2013;32(1):23-30.
14. Glanville AR. Antibody-mediated rejection in lung transplantation: myth or reality? J Heart Lung Transplant. 2009;29(4):395-400.
15. Nawrot TS, Vos R, Jacobs L, Verleden SE, Wauters S, Mertens V, et al. The impact of traffic air pollution on bronchiolitis obliterans syndrome and mortality after lung transplantation. Thorax. 2011;66(9):748-54.
16. Goers TA, Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol. 2008;180(7):4487-94.
17. Yoshida S, Haque A, Mizobuchi T, Iwata T, Chiyo M, Webb TJ, et al. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant. 2006;6(4):724-35. (Pubitemid 43345010)
18. Lee JC, Christie JD. Primary graft dysfunction. Proc Am Thorac Soc. 2009;6(1):39-46.
19. Willis BC, Borok Z. Epithelial-mesenchymal transition: potential role in obliterative bronchiolitis? Thorax. 2009;64(9):742-3.
20. Ward C, Forrest IA, Murphy DM, Johnson GE, Robertson H, Cawston TE, et al. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax. 2005;60(10):865-71. (Pubitemid 41475217)
21. Jiang X, Khan MA, Tian W, Beilke J, Natarajan R, Kosek J, et al. Adenovirus-mediated HIF-1alpha gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest. 2011;121(6):2336-49.
22. Andersson-Sjoland A, Erjefalt JS, Bjermer L, Eriksson L, Westergren-Thorsson G. Fibrocytes are associated with vascular and parenchymal remodelling in patients with obliterative bronchiolitis. Resp Res. 2009;10:103.
23. Hachem RR, Chakinala MM, Yusen RD, Lynch JP, Aloush AA, Patterson GA, et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med. 2004;169(4):468-72. (Pubitemid 38187118)
24. Lama VN, Murray S, Mumford JA, Flaherty KR, Chang A, Toews GB, et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med. 2005;172(3):379-83. (Pubitemid 41026150)
25. Van Muylem A, Knoop C, Estenne M. Early detection of chronic pulmonary allograft dysfunction by exhaled biomarkers. Am J Respir Crit Care Med. 2007;175(7):731-6. (Pubitemid 46536490)
26. Soter S, Kelemen K, Barta I, Valyon M, Csiszer E, Antus B. Exhaled breath condensate pH in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation. 2011;91(7):793-7.
27. Haberman B, Doan ML, Smith EO, Schecter MG, Mallory GB, Elidemir O. Serum KL-6 level and the development of bronchiolitis obliterans syndrome in lung transplant recipients. Pediatr Transplant. 2010;14(7):903-8.
28. Ohshimo S, Bonella F, Sommerwerck U, Teschler H, Kamler M, Jakob HG, et al. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation. J Heart Lung Transplant. 2011;30(12):1374-80.
29. LaPar DJ, Burdick MD, Emaminia A, Harris DA, Strieter BA, Liu L, et al. Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann Thorac Surg. 2011;92(2):470-7.
30. Salama M, Jaksch P, Andrukhova O, Taghavi S, Klepetko W, Aharinejad S. Endothelin-1 is a useful biomarker for early detection of bronchiolitis obliterans in lung transplant recipients. J Thorac Cardiovasc Surg. 2010;140(6):1422-7.
31. Kastelijn EA, Rijkers GT, Van Moorsel CH, Zanen P, Kwakkel-van Erp JM, Van De Graaf EA, et al. Systemic and exhaled cytokine and chemokine profiles are associated with the development of bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2010;29(9):997-1008.
32. Wolf T, Oumeraci T, Gottlieb J, Pich A, Brors B, Eils R, et al. Proteomic bronchiolitis obliterans syndrome risk monitoring in lung transplant recipients. Transplantation. 2011;92(4):477-85.
33. Ofek E, Sato M, Saito T, Wagnetz U, Roberts HC, Chaparro C, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Modern pathology. 2013;26(3):350-6.
34. Keith DS, Cantarovich M, Paraskevas S, Tchervenkov J. Recipient age and risk of chronic allograft nephropathy in primary deceased donor kidney transplant. Transplant Int. 2006;19(8):649-56.
35. LaRosa C, Baluarte HJ, Meyers KE. Outcomes in pediatric solid-organ transplantation. Pediatr Transplant. 2011;15(2):128-41.
36. Dew MA, Dabbs AD, Myaskovsky L, Shyu S, Shellmer DA, DiMartini AF, et al. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation. 2009;88(5):736-46.
37. Pinsky BW, Takemoto SK, Lentine KL, Burroughs TE, Schnitzler MA, Salvalaggio PR. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant. 2009;9(11):2597-606.
38. Fredericks EM, Dore-Stites D. Adherence to immunosuppressants: how can it be improved in adolescent organ transplant recipients? Curr Opin Organ Transplant. 2010;15(5):614-20.
39. Fine RN, Becker Y, De Geest S, Eisen H, Ettenger R, Evans R, et al. Nonadherence consensus conference summary report. Am J Transplant. 2009;9(1):35-41.
40. Schafer-Keller P, Steiger J, Bock A, Denhaerynck K, De Geest S. Diagnostic accuracy of measurement methods to assess non-adherence to immunosuppressive drugs in kidney transplant recipients. Am J Transplant. 2008;8(3):616-26. (Pubitemid 351287554)
41. Stuber ML, Shemesh E, Seacord D, Washington J 3rd, Hellemann G, McDiarmid S. Evaluating non-adherence to immunosuppressant medications in pediatric liver transplant recipients. Pediatr Transplant. 2008;12(3):284-8. (Pubitemid 351589456)
42. Kahana SY, Frazier TW, Drotar D. Preliminary quantitative investigation of predictors of treatment non-adherence in pediatric transplantation: a brief report. Pediatr Transplant. 2008;12(6):656-60.
43. Simons LE, McCormick ML, Devine K, Blount RL. Medication barriers predict adolescent transplant recipients' adherence and clinical outcomes at 18-month follow-up. J Ped Psychol. 2010;35(9):1038-48.
44. Bell LE, Bartosh SM, Davis CL, Dobbels F, Al-Uzri A, Lotstein D, et al. Adolescent Transition to Adult Care in Solid Organ Transplantation: a consensus conference report. Am J Transplant. 2008;8(11):2230-42.
45. Graves MM, Roberts MC, Rapoff M, Boyer A. The efficacy of adherence interventions for chronically ill children: a meta-analytic review. J Ped Psychol. 2010;35(4):368-82.
46. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Int Med. 2000;160(14):2101-7. (Pubitemid 30482715)
47. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev. 2005;2005(4):CD000011.
48. Cushing CC, Steele RG. A meta-analytic review of eHealth interventions for pediatric health promoting and maintaining behaviors. J Pediatr Psychol. 2010;35(9):937-49.
49. Miloh T, Annunziato R, Arnon R, Warshaw J, Parkar S, Suchy FJ, et al. Improved adherence and outcomes for pediatric liver transplant recipients by using text messaging. Pediatrics. 2009;124(5):e844-50.
50. Glanville AR. Antibody-mediated rejection in lung transplantation: turning myth into reality. J Heart Lung Transplant. 2012;32(1):12-3.
51. McDonald S, Russ G, Campbell S, Chadban S. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant. 2007;7(5):1201-8. (Pubitemid 46646787)
52. Walsh RC, Brailey P, Girnita A, Alloway RR, Shields AR, Wall GE, et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation. 2011;91(11):1218-26.
53. Berry G, Burke M, Andersen C, Angelini A, Bruneval P, Calbrese F, et al. Pathology of pulmonary antibody-mediated rejection, update from the Pathology Council of the ISHLT. J Heart Lung Transplant. 2012;32(1):14-21.
54. Daoud AH, Betensley AD. Diagnosis and treatment of antibody mediated rejection in lung transplantation: a retrospective case series. Transplant Immunol. 2012;28(1):1-5.
55. Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant. 2005;9(3):408-15. (Pubitemid 40780375)
56. Jordan SC, Vo AA, Toyoda M, Tyan D, Nast CC. Post-transplant therapy with high-dose intravenous gammaglobulin: applications to treatment of antibody-mediated rejection. Pediatr Transplant. 2005;9(2):155-61. (Pubitemid 40476841)
57. Faro A, Mallory GB, Visner GA, Elidemir O, Mogayzel PJ Jr, Danziger-Isakov L, et al. American Society of Transplantation executive summary on pediatric lung transplantation. Am J Transplant. 2007;7(2):285-92. (Pubitemid 46096321)
58. Knoop C, Estenne M. Acute and chronic rejection after lung transplantation. Sem Resp Crit Care Med. 2006;27(5):521-33. (Pubitemid 44672555)
59. Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006;354(2):141-50. (Pubitemid 43076711)
60. Groves S, Galazka M, Johnson B, Corcoran T, Verceles A, Britt E, et al. Inhaled cyclosporine and pulmonary function in lung transplant recipients. J Aero Med Drug Delivery. 2010;23(1):31-9.
61. Thacker J, Toyoda Y. Lung and heart-lung transplantation at University of Pittsburgh: 1982-2009. Clin Transplant. 2009:179-95.
62. Verleden GM, Lievens Y, Dupont LJ, Van Raemdonck DE, De Vleeschauwer SI, Vos R, et al. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation. Transplant Proceed. 2009;41(5):1816-20.
63. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168(1):121-5. (Pubitemid 37046642)
64. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85(1):36-41.
65. Vos R, Vanaudenaerde BM, Ottevaere A, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transpl. 2010;29(12):1358-68.
66. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2012;37(1):164-72.
67. Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med. 2003;167(9):1271-8. (Pubitemid 36555101)
68. Muller C, Gorler H, Ballmann M, Gottlieb J, Simon AR, Struber M, et al. Pulmonary retransplantation in paediatric patients: a justified therapeutic option? A single-centre experience. Eur J Cardiothorac Surg. 39(2):201-5.
69. Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2010;29(4):424-31.
70. Verleden GM, Verleden SE, Vos R, De Vleeschauwer SI, Dupont LJ, Van Raemdonck DE, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transplant Int. 2011;24(7):651-6.
71. Bizargity P, Liu K, Wang L, Hancock WW, Visner GA. Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection. Transplantation. 2012;94(2):114-22.
72. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, Meyts I, Bullens DM, Reynders V, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2008;8(9):1911-20.
73. Sinclair K, Yerkovich ST, Chambers DC. Mesenchymal stem cells and the lung. Respirology. 2013;18(3):397-411.